JP2011157403A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011157403A5 JP2011157403A5 JP2011116366A JP2011116366A JP2011157403A5 JP 2011157403 A5 JP2011157403 A5 JP 2011157403A5 JP 2011116366 A JP2011116366 A JP 2011116366A JP 2011116366 A JP2011116366 A JP 2011116366A JP 2011157403 A5 JP2011157403 A5 JP 2011157403A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- day
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13703899P | 1999-06-01 | 1999-06-01 | |
| US60/137,038 | 1999-06-01 | ||
| US18533600P | 2000-02-29 | 2000-02-29 | |
| US60/185,336 | 2000-02-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000620987A Division JP4817503B2 (ja) | 1999-06-01 | 2000-06-01 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012130177A Division JP2012176983A (ja) | 1999-06-01 | 2012-06-07 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| JP2014165702A Division JP5960762B2 (ja) | 1999-06-01 | 2014-08-18 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011157403A JP2011157403A (ja) | 2011-08-18 |
| JP2011157403A5 true JP2011157403A5 (enExample) | 2012-07-26 |
| JP5623335B2 JP5623335B2 (ja) | 2014-11-12 |
Family
ID=26834850
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000620987A Expired - Lifetime JP4817503B2 (ja) | 1999-06-01 | 2000-06-01 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| JP2007136041A Pending JP2007277253A (ja) | 1999-06-01 | 2007-05-22 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| JP2011116366A Expired - Lifetime JP5623335B2 (ja) | 1999-06-01 | 2011-05-24 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| JP2012130177A Pending JP2012176983A (ja) | 1999-06-01 | 2012-06-07 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| JP2014165702A Expired - Lifetime JP5960762B2 (ja) | 1999-06-01 | 2014-08-18 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| JP2016060029A Withdrawn JP2016121184A (ja) | 1999-06-01 | 2016-03-24 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000620987A Expired - Lifetime JP4817503B2 (ja) | 1999-06-01 | 2000-06-01 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| JP2007136041A Pending JP2007277253A (ja) | 1999-06-01 | 2007-05-22 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012130177A Pending JP2012176983A (ja) | 1999-06-01 | 2012-06-07 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| JP2014165702A Expired - Lifetime JP5960762B2 (ja) | 1999-06-01 | 2014-08-18 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
| JP2016060029A Withdrawn JP2016121184A (ja) | 1999-06-01 | 2016-03-24 | Ｖｌａ−１に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US6955810B2 (enExample) |
| EP (3) | EP1488806B1 (enExample) |
| JP (6) | JP4817503B2 (enExample) |
| CN (1) | CN1309419C (enExample) |
| AU (2) | AU783989B2 (enExample) |
| BG (1) | BG65579B1 (enExample) |
| BR (1) | BR0011250A (enExample) |
| CA (1) | CA2375827C (enExample) |
| CY (1) | CY1116042T1 (enExample) |
| CZ (1) | CZ300710B6 (enExample) |
| DK (2) | DK2314315T3 (enExample) |
| EA (1) | EA011384B1 (enExample) |
| EE (1) | EE200100651A (enExample) |
| ES (2) | ES2529706T3 (enExample) |
| GE (1) | GEP20063774B (enExample) |
| HK (1) | HK1043320A1 (enExample) |
| HU (1) | HUP0202568A3 (enExample) |
| IL (2) | IL146508A0 (enExample) |
| IS (1) | IS6179A (enExample) |
| MX (1) | MXPA01012388A (enExample) |
| NO (1) | NO20015864L (enExample) |
| NZ (1) | NZ515686A (enExample) |
| PT (2) | PT1488806E (enExample) |
| SI (2) | SI2314315T1 (enExample) |
| SK (1) | SK17232001A3 (enExample) |
| TR (1) | TR200103432T2 (enExample) |
| WO (1) | WO2000072881A1 (enExample) |
| YU (1) | YU85501A (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ300710B6 (cs) * | 1999-06-01 | 2009-07-22 | Biogen Idec Ma Inc. | Použití blokující monoklonální protilátky proti VLA-1 pro výrobu farmaceutického prípravku k lécení zánetlivých onemocnení |
| UA83791C2 (ru) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
| WO2003068262A1 (en) * | 2002-02-14 | 2003-08-21 | Biogen, Inc. | Alpha1beta1 antagonists for treatment of atherosclerosis |
| US7348002B2 (en) * | 2002-11-01 | 2008-03-25 | Boys Town National Research Hospital | Inducible ligand for α1β1 integrin and uses |
| WO2005004800A2 (en) * | 2003-06-20 | 2005-01-20 | Morehouse School Of Medicine | Trypanosome derived apoptotic factors (taf) |
| US20080093950A1 (en) * | 2003-12-09 | 2008-04-24 | Electrotechnologies Selem. Inc | Polyphase Claw-Pole Machines With a Segmented Magnetic Circuit |
| US20050136055A1 (en) * | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| WO2006133286A2 (en) * | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| US10119979B2 (en) * | 2006-05-25 | 2018-11-06 | Biogen Ma Inc. | Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies |
| WO2009135953A2 (en) * | 2008-05-09 | 2009-11-12 | Ablynx Nv | Amino acid sequences directed against integrins and uses thereof |
| JP6324720B2 (ja) * | 2010-06-18 | 2018-05-16 | エックスバイオテク, インコーポレイテッドXbiotech, Inc. | 関節炎治療 |
| US20140017261A1 (en) * | 2011-02-03 | 2014-01-16 | Mark Totoritis | Selection and treatment of subjects |
| NZ629204A (en) | 2012-02-16 | 2016-09-30 | Santarus Inc | Anti-vla1 (cd49a) antibody pharmaceutical compositions |
| EP3655011A4 (en) * | 2017-07-20 | 2021-03-31 | University Of Virginia Patent Foundation | PROCEDURES FOR THE TREATMENT OR PREVENTION OF A NEUROLOGICAL DISORDER OF THE IMMUNE SYSTEM |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5391481A (en) | 1990-08-31 | 1995-02-21 | The Trustees Of Columbia University | Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof |
| DE69230142T2 (de) | 1991-05-15 | 2000-03-09 | Cambridge Antibody Technology Ltd. | Verfahren zur herstellung von spezifischen bindungspaargliedern |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DK0626861T4 (da) | 1992-01-13 | 2004-08-16 | Biogen Inc | Behandling af astma. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
| DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
| WO1994017828A2 (en) | 1993-02-09 | 1994-08-18 | Biogen, Inc. | Treatment for insulin dependent diabetes |
| US6111598A (en) | 1993-11-12 | 2000-08-29 | Peveo, Inc. | System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| JP4115517B2 (ja) | 1994-01-25 | 2008-07-09 | エラン ファーマシューティカルズ， インコーポレイテッド | 白血球付着分子 ｖｌａ−４に対するヒト化抗体 |
| US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| ATE195428T1 (de) | 1994-04-26 | 2000-09-15 | Kanebo Ltd | Arznei für rheumatoide arthritis |
| JPH08131185A (ja) * | 1994-11-14 | 1996-05-28 | Sumitomo Electric Ind Ltd | マウスｖｌａ−１分子に対するモノクローナル抗体 |
| JPH08160972A (ja) | 1994-12-01 | 1996-06-21 | Sega Enterp Ltd | エフェクト制御方法、制御装置およびこれを利用したカラオケ装置 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| GB9516399D0 (en) | 1995-08-10 | 1995-10-11 | Camelot Superabsorbents Ltd | Process for the production of water-absorbing compositions |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| CA2230759C (en) | 1995-08-29 | 2012-02-21 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| GB9519667D0 (en) | 1995-09-27 | 1995-11-29 | Univ Manchester | Pharmaceutical composition |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| FR2745912B1 (fr) * | 1996-03-08 | 1998-05-29 | Lorraine Laminage | Procede et dispositif de controle de la soudabilite de toles sandwich |
| US6127524A (en) | 1996-10-18 | 2000-10-03 | Dade Behring Inc. | Binding molecules and computer-based methods of increasing the binding affinity thereof |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| DK0999853T3 (da) | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
| SI1079843T1 (sl) | 1998-05-22 | 2007-10-31 | Bpys Town Nat Res Hospital | Uporaba inhibitorjev receptorja alfa1beta1-integrina in inhibitorjev TGF-beta1 pri zdravljenju ledvične bolezni |
| DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| WO2000020459A1 (en) | 1998-10-06 | 2000-04-13 | Biogen, Inc. | Crystals of the alpha 1 beta 1 integrin i-domain and their use |
| HK1041452B (en) * | 1999-04-22 | 2005-10-14 | Biogen Idec Ma Inc. | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit |
| CZ300710B6 (cs) * | 1999-06-01 | 2009-07-22 | Biogen Idec Ma Inc. | Použití blokující monoklonální protilátky proti VLA-1 pro výrobu farmaceutického prípravku k lécení zánetlivých onemocnení |
| US7601125B1 (en) | 1999-06-17 | 2009-10-13 | Desinger Kai | Surgical, grooved director for collecting tissue in a minimally invasive manner |
| WO2001073444A2 (en) | 2000-03-28 | 2001-10-04 | Cambridge University Technical Services Limited | Receptor/peptide crystal structure for identification of inhibitors |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| DE10028402A1 (de) | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
| US7153944B2 (en) | 2000-07-31 | 2006-12-26 | The General Hospital Corporation | High affinity integrin polypeptides and uses thereof |
| UA83791C2 (ru) | 2001-04-13 | 2008-08-26 | Байоджен Айдек Ма Инк. | Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 |
| WO2003068262A1 (en) | 2002-02-14 | 2003-08-21 | Biogen, Inc. | Alpha1beta1 antagonists for treatment of atherosclerosis |
| KR101115797B1 (ko) | 2002-08-01 | 2012-07-27 | 이뮤노메딕스, 인코오포레이티드 | 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법 |
| US20040208870A1 (en) | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| WO2005019200A2 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof |
| WO2005016883A2 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Acrylamide derivatives as vla-1 integrin antagonists and uses thereof |
| US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| WO2006133286A2 (en) | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
| US10119979B2 (en) | 2006-05-25 | 2018-11-06 | Biogen Ma Inc. | Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies |
| JP4951596B2 (ja) | 2008-07-31 | 2012-06-13 | 株式会社日立製作所 | 冷却システム及び電子装置 |
| CA2754528A1 (en) | 2009-03-06 | 2010-09-10 | Genetech, Inc. | Antibody formulation |
| ES2765657T3 (es) | 2009-12-21 | 2020-06-10 | Hoffmann La Roche | Formulación farmacéutica de bevacizumab |
| US20140017261A1 (en) | 2011-02-03 | 2014-01-16 | Mark Totoritis | Selection and treatment of subjects |
| JP5662565B2 (ja) | 2012-01-11 | 2015-02-04 | パナソニックＩｐマネジメント株式会社 | 圧接型半導体装置及びその製造方法 |
| NZ629204A (en) | 2012-02-16 | 2016-09-30 | Santarus Inc | Anti-vla1 (cd49a) antibody pharmaceutical compositions |
-
2000
- 2000-06-01 CZ CZ20014249A patent/CZ300710B6/cs not_active IP Right Cessation
- 2000-06-01 SI SI200031087T patent/SI2314315T1/sl unknown
- 2000-06-01 CA CA2375827A patent/CA2375827C/en not_active Expired - Lifetime
- 2000-06-01 TR TR2001/03432T patent/TR200103432T2/xx unknown
- 2000-06-01 JP JP2000620987A patent/JP4817503B2/ja not_active Expired - Lifetime
- 2000-06-01 HU HU0202568A patent/HUP0202568A3/hu unknown
- 2000-06-01 SI SI200031089T patent/SI1488806T1/sl unknown
- 2000-06-01 GE GE5125A patent/GEP20063774B/en unknown
- 2000-06-01 IL IL14650800A patent/IL146508A0/xx active IP Right Grant
- 2000-06-01 DK DK10185467.7T patent/DK2314315T3/en active
- 2000-06-01 ES ES10185467.7T patent/ES2529706T3/es not_active Expired - Lifetime
- 2000-06-01 AU AU57248/00A patent/AU783989B2/en not_active Expired
- 2000-06-01 NZ NZ515686A patent/NZ515686A/en unknown
- 2000-06-01 SK SK1723-2001A patent/SK17232001A3/sk unknown
- 2000-06-01 MX MXPA01012388A patent/MXPA01012388A/es active IP Right Grant
- 2000-06-01 YU YU85501A patent/YU85501A/sh unknown
- 2000-06-01 BR BR0011250-0A patent/BR0011250A/pt not_active Application Discontinuation
- 2000-06-01 ES ES04018151.3T patent/ES2557768T3/es not_active Expired - Lifetime
- 2000-06-01 PT PT40181513T patent/PT1488806E/pt unknown
- 2000-06-01 DK DK04018151.3T patent/DK1488806T3/en active
- 2000-06-01 EP EP04018151.3A patent/EP1488806B1/en not_active Expired - Lifetime
- 2000-06-01 PT PT10185467T patent/PT2314315E/pt unknown
- 2000-06-01 HK HK02105185.2A patent/HK1043320A1/zh unknown
- 2000-06-01 EA EA200400930A patent/EA011384B1/ru not_active IP Right Cessation
- 2000-06-01 EP EP10185467.7A patent/EP2314315B1/en not_active Expired - Lifetime
- 2000-06-01 WO PCT/US2000/015004 patent/WO2000072881A1/en not_active Ceased
- 2000-06-01 EE EEP200100651A patent/EE200100651A/xx unknown
- 2000-06-01 CN CNB008084289A patent/CN1309419C/zh not_active Expired - Lifetime
- 2000-06-01 EP EP00942654A patent/EP1181054A1/en not_active Withdrawn
-
2001
- 2001-11-15 IL IL146508A patent/IL146508A/en not_active IP Right Cessation
- 2001-11-28 IS IS6179A patent/IS6179A/is unknown
- 2001-11-30 NO NO20015864A patent/NO20015864L/no not_active Application Discontinuation
- 2001-11-30 US US09/996,738 patent/US6955810B2/en not_active Expired - Lifetime
- 2001-12-17 BG BG106226A patent/BG65579B1/bg unknown
-
2005
- 2005-04-18 US US11/108,581 patent/US7462353B2/en not_active Expired - Lifetime
-
2006
- 2006-04-12 AU AU2006201540A patent/AU2006201540A1/en not_active Abandoned
-
2007
- 2007-05-22 JP JP2007136041A patent/JP2007277253A/ja active Pending
-
2008
- 2008-11-11 US US12/268,459 patent/US8084031B2/en not_active Expired - Fee Related
-
2011
- 2011-05-24 JP JP2011116366A patent/JP5623335B2/ja not_active Expired - Lifetime
- 2011-11-15 US US13/296,778 patent/US8557240B2/en not_active Expired - Fee Related
-
2012
- 2012-06-07 JP JP2012130177A patent/JP2012176983A/ja active Pending
-
2013
- 2013-09-09 US US14/021,547 patent/US9902774B2/en not_active Expired - Fee Related
-
2014
- 2014-08-18 JP JP2014165702A patent/JP5960762B2/ja not_active Expired - Lifetime
-
2015
- 2015-02-20 CY CY20151100186T patent/CY1116042T1/el unknown
-
2016
- 2016-03-24 JP JP2016060029A patent/JP2016121184A/ja not_active Withdrawn